A Phase 2b Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Chronic Painful Diabetic Peripheral Neuropathy (DPN).

Trial Profile

A Phase 2b Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Chronic Painful Diabetic Peripheral Neuropathy (DPN).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Mar 2009 Status changed from active, no longer recruiting to discontinued due to insufficient clinical efficacy observed in previous studies conducted in postherpetic neuralgia, as reported by clinicaltrials.gov.
    • 10 Mar 2009 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Feb 2009 Pfizer has decided to discontinue development of this drug, as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top